← board
RADX
distress 1/10 · well-funded / low risk$4.290%today-60% from 52w high
Revenue
pre-revenue
Liquidity
$29M
Runway
—
Shares 1y
—
Price & events
-15.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-0.9%
1W
-0.5%
1M
-7.5%
3M
-15.0%
6M
-2.7%
1Y
—
2Y
—
5Y
-75.7%
All
Overview
- Market Cap
- $10.15B
- Volume
- 0
- 52 Week Range
- $4.00 – $10.63
- Total Shares
- 2.36B
- Float Shares
- 8.29M
- Short %
- 1.00%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 2.54%
- Beta
- 0.80
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: 2,364,949,502 · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-06-04HC Wainwright & Co.Buy
- 2025-12-16B. Riley SecuritiesBuy
- 2025-11-26B. Riley SecuritiesBuy
- 2025-07-21Brookline CapitalBuy
- 2025-05-01Maxim GroupBuy
- 2025-03-12B. Riley SecuritiesBuy
Competitors
- none identified
Recent news
- none
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.